AU613810B2

AU613810B2 - Cisplatin hypertonic solution

Info

Publication number: AU613810B2
Application number: AU44683/89A
Authority: AU
Inventors: Joseph B. Bogardus; Kenneth W. Douglas; Murray A. Kaplan; Robert K. Perrone
Original assignee: Bristol Myers Squibb Co
Current assignee: Bristol Myers Squibb Co
Priority date: 1988-11-14
Filing date: 1989-11-14
Publication date: 1991-08-08
Anticipated expiration: 2009-11-14
Also published as: AU4468389A; FI895340A7; IL92292A0; YU216689A; DD292135A5; ZA898652B; EP0369714A1; FI895340A0; NZ231363A; HUT52373A; NO894505D0; DK567689A; DK567689D0; OA10033A; HU208074B; HU895890D0; PT92300A; NO894505L; JPH0321252A

Description

_i T/ jll_i

AUSTRALIA

Patents Act f~3 COMPLETE SPECIFICATION

(ORIGINAL)

Class Application Number: Lodged: Complete Specification Lodged: Accepted: Published: Priority Related Art: Int. Class Applicant(s): sc^ifia Bristol-Myers Company 345 Park Avenue, New York, New York, 10154, UNITED STATES OF AMERICA Address for Service is: PHILLIPS ORMONDE FITZPATRICK Patent and Trade Mark Attorneys 367 Collins Street Melbourne 3000 AUSTRALIA Complete Specification for the invention entitled: CISPLATIN HYPERTONIC SOLUTION Our Ref 148180 POF Code: 1.490/1490 The following statement is a full description of this invention, including the best method of performing it known to applicant(s): 1- 6006 j 17 i BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to pharmaceutical compositions of cisplatin.

I 2. Background Art Cisplatin has emerged as an important antineoplastic agent and is currently approved in the United States for the treatment of metastatic testicular cancer, metastatic o0-. ovarian cancer, and advanced bladder cancer.

o° Cisplatin is commonly available as a lyophilized powder which is reconstituted with Water for Injection, U.S.P.

os before use. For example, the Division of Cancer Treatment, 00"' National Cancer Institute provides investigators lyophilized cisplatin which upon reconstitution with water yields a solution containing for each ml, 1 mg of cisplatin, 9 mg of sodium chloride, and 10 mg of mannitol; the pH of the ooo resulting solution is about 3.5 to 5.5 (NCI Investigational Drugs, Pharmaceutical Data, 1985, pp 74-77). US Patent 4,670,262 discloses a freeze-dried cisplatin composition containing a lower alcohol. Ready-to-use cisplatin solutions have been disclosed in US Patent 4,310,515 and European Application 143,478. A recent Japanese Kokai ,62/292,722 (Derwent No. 88-032992) discloses a solution of :cisplatin in physiological saline and containing magnesium chloride to lower nephrotoxicity. However, due to the inherent instability of cisplatin in aqueous environment, the reconstituted lyophilized cisplatin or the ready-to-use cisplatin solutions show formation of considerable amounts of "aquated platinum species". These degradation products 1Ii have been implicated as possible agents for cisplatin toxicities and therefore it would be desirable to have formulations containing as little as possible of these species.

Greene et al (Am. J. Hosp. Pharmacy, 1979, 36:38-43), using NCI cisplatin formulations, showed that in less than one hour after reconstitution with 0.9% sodium chloride solution at room temperature approximately 3% of cisplatin was degraded and that level remained constant for 24 hours; even greater cisplatin loss was observed at lower sodiu chloride concentrations. The pH of the cisplatin saline solutions in the Greene study was approximately 4. Hincal 00 oo et al Parenteral Drug Assoc., 1979, 33:107-16) reported o the stabilizing effect of up to 0.9% sodium chloride on 0 0 cisplatin aqueous solutions over 24 hours. In the same °study cisplatin was found to be unstable in 5% sodium bicarbonate solution of pH 7.5 at 25 0 C, and it was suggested that alkaline solution of cisplatin should be avoided since the equilibria may be unfavorably shifted at higher pH.

Litterst (Toxicol. Appl. Pharmacol., 1981, 61:99-108) °o o studied the toxicity in mice of cisplatin administered in a hypertonic solution containing 4.5% sodium chloride. The S.0.o o cisplatin used was obtained from the Division of Cancer Treatment, National Cancer Institute. The study showed that cisplatin administered in high salt solution is significantly less toxic than the drug administered in water or normal saline.

Aamdal et al Natl. Cancer Inst., 1984, 73:743-752) also prepared cisplatin in hypertonic saline solution using commercially available formulations containing in addition to cisplatin, mannitol and sodium chloride. Solutions -2 containing 1 mg/ml cisplatin and and 6.0% (w/v) sodium chloride were prepared and the effect of high sodium chloride concentrations on antitumor activity of cisplatin was evaluated in mice. The lyophilized cisplatin used was obtained from Farmitalia Carlo Erba (Milan, Italy) and Bristol Laboratories (Syracuse, NY).

Ozols et al (Ann. Internal Med., 1984, 100:19-24) administered 40 mg/m 2 cisplatin to humans as a 30 minute infusion in 250 ml 3% saline. Assuming a body surface area 2 of 2 m the solution administered would have a cisplatin concentration of 0.32 mg/ml.

o a oa In the three studies cited above, the pH of the o solutions was not adjusted and the stability of the solutions was not evaluated. We have determined the pH of S° one vial of cisplatin reconstituted with 5% sodium chloride S4 and it was 4.75. This is consistent with the pH range given in the NCI monograph. It is expected that reconstitution with 0.9% sodium chloride would yield a solution with similar. pH as concentration of salt appears to have little °o effect on pH.

SUMMARY OF THE INVENTION oo The present invention provides a stable ready-to-use cisplatin aqueous solution containing for each ml up to 1 mg of cisplatin, and a pharmaceutically acceptable source of chloride ion in amount equivalent to that produced by about to 100 mg of sodium chloride; the pH of the solution may range from about 5.0 to about A further aspect of the invention provides a cisplatin pharmaceutical dosage form for reconstitution with 3 I J Ur II ~IClr__~ I o o a 0 oo o o a o So a a o parenteral diluent which comprises for each part of cisplatin, 25 to 100 parts of a pharmaceutically acceptable source of chloride ion, said dosage form being substantially free of lower alkanol.

DETAILED DESCRIPTION OF THE INVENTION Cisplatin is known to be unstable in aqueous solutions and rapidly establishes equilibrium with the formation of various "aquated platinum species", dimers, and trimers (Fairlie and Whitehouse, Biochem. Pharmacol., 31, 933 (1982)). The formation of these decomposition products represents not only a loss of cisplatin activity but also an increase of substances potentially more toxic than cisplatin. Although studies have shown cisplatin in 0.9% sodium chloride solution decomposes to a lesser extent than in solutions with lower sodium chloride concentration, the loss of cisplatin is still approximately 3% in 24 hours a't room temperature. Furthermore, because the equilibrium is unfavorably shifted to degradation products under alkaline conditions, heretofore available ready-to-use solutions all have pH values ranging from about 2 to about 4. Such acidic injectable solutions may be highly irritating and thus an added burden to patients undergoing chemotherapy.

It has been discovered that the above objections may be overcome by supplying to aqueous cisplatin solutions a high concentration of chloride ion thereby enabling the preparation of stable ready-to-use cisplatin solutions that are closer to physiological pH than those currently available.

The ready-to-use cisplatin solution of the present invention contains up to 1 mg/ml of cisplatin, and a 4 rnP i L\ L I. pharmaceutically acceptable source of chloride ion in amc:unt equivalent to that produced by about 20 to about 100 mg/ml of sodium chloride. The pH of the solution is adjusted to about 5.0 7.5. Preferably, the cisplatin concentration is from about 0.2 to about 1.0 mg/ml. The preferred source of chloride ion is sodium chloride which is preferably present in concentration of about 40 to about 60 mg/ml with about mg/ml being the most preferred. We found that although sodium chloride may be present in concentration higher than mg/ml, any higher salt concentrations do not confer significant additional stability to the ready-to-use cisplatin solutions. A preferred pH range for the solution is from about 5.6 to about 6.5, and most preferably from o 0 0 rabout 6.0 to about 6.5. The cisplatin solution of the 0 o present invention may be used in substantially the same oooo manner as known ready-to-use cisplatin solutions.

ooo 00ooo0 GooI The solution of the present invention is readily prepared by dissolving cisplatin in the desired concentration in water containing sodium chloride. It is preferred to dissolve the sodium chloride first in the water °0o' o and then add cisplatin, because of the above-mentioned 00 00o formation of aquated species. Although sodium chloride is the preferred source of chloride ion, other pharmaceutically o acceptable sources of chloride ion, such as potassium chloride, calcium chloride, N-methylglucamine hydrochloride, choline chloride, and the like may also be used. If oooo level by addition of a pharmaceutically acceptable acid such as hydrochloric acid or a pharmaceutically acceptable base such as sodium hydroxide. The solution may be either substantially free of other ingredients or it may contain other pharmaceutical excipients such as mannitol.

Preservatives may also be added if desired. The bulk i cisplatin should be protected from light; therefore, the preparative process is preferably carried out under reduced light exposure, either in the dark or in highly-subdued light.

Instruction for the preparation of a cisplatin solution containing 1 mg/ml. cisplatin and 50 mg/ml sodium chloride is provided as follows: 1. Place approximately 900 ml of water for injection, U.S.P. at 20 30°C in a suitable container.

2. Add and dissolve 50 g of sodium chloride with stirring.

0 00 3. In the dark (or in highly-subdued light), cautiously "o sprinkle in 1.0 g of cisplatin over a 5-minute interval o and with rapid stirring. Stir until dissolved 0o 0 (approximately 2 4 hours is required).

4. Add 0.1 1.0 N NaOH to adjust pH to about 5.5 Stir for 0.5 hour.

o oo0000 000 0 5. Bring the volume to 1 L with Water for Injection, U.S.P. Stir in the dark for an additional 1 hour.

6. Using aseptic techniques throughout and protecting the solution from light: a) Pass the solution through a suitable 0.22 micron membrane filter.

b) Collect the filtrate in a suitable container.

c) Fill required volumes into suitable brown-glass vials. Seal with suitable stoppers (20 mmDaikyo) and aluminum closures.

-6 Yhs Accordingly, a cisplatin solution containing 1 mg/ml cisplatin, 50 mg/ml sodium chloride and having a pH of was prepared. Similarly, by substituting 0.5 g for the g of cisplatin and 25 g for the 50 g of sodium chloride previously used, a solution containing 0.5 mg/ml cisplatin and 25 mg sodium chloride was obtained.

Cisplatin solutions containing about 0.6 mg/ml or higher of cisplatin may deposit cisplatin crystals if kept at 4 0 C. The crystals, however, may be re-dissolved by shaking and warming to 400C. Solutions containing 0.5 mg/ml or less of cisplatin do not deposit cisplatin crystals when stored at 4°C.

The stability of solutions containing 1 mg/ml cisplatin, either 50 mg/ml or 9 mg/ml of sodium chloride and having a pH of 2.5, 4.2 and 6.5 was evaluated at 250, 370, and 450. Samples were periodically assayed for cisplatin, trichloroamminoplatinum (TCAP), and aquated species, using high performance liquid chromatography. The results are presented in Table I.

oQ 00 0a 0 0 0 Co 0 0 0

O

Cao 7 i-d -L o G o oo0 Table I. Dearadation of 1 mq/m- ci.sp;latinoSolution o C ~i u Moh c o ooo ooo o Moi-hs 25 C S o o oo co o0 0 o 0 0 0 onh~ 7C eeks 45 0

C

Original 2 3 4 6 12 1 2 3 4 1 2 4 8 pH 0.9NaCl cisplatin Rem.

TCAP

7 Aquated sp.

5HaC1 7 cisplatin Rem.

7 TCAP 7 Aquated sp.

98.5 0 0 2.2 1.2 99.0 0.5 3.0 99.7 0.68 0 100.7 0.2 4.4 102.0 .39 0 97.2 98.0 0.45 1.3 3.2 2.6 95.4 0.8 1.6 96.7 1.1 2.2 99.2 2.7 0 96.8 2.4 2.9 96.4 2.0 1.8 96.9 5.1 0 98.2 0.18 0.8 99.7 0.29 0 96.6 0.44 5.4 99.2 0.58 0 102.1 0.1 0 99.7 0.58 0 100.6 1.4 0 ph 4.2 0. 9;aaC1 7 cisplatin Rem.

Z TCAP Z Aquated sp.

98.7 0 0 2.0 1.3 100.9 0 0.19 0 0 99.5 0.27 3.0 99.8 0.58 0 101.8 0.2 1.2 102.1 0.29 0 97.3 0.45 3.2 97.9 0.29 1.4 99.0 0.8 2.0 100.6 0.87 0 95.8 0.6 1.0 95.5 0.68 0 97.5 0.6 1.3 98.2 1.9 97.2 1.4 3.7 97.1 2.8 0.8 99.0 0.1 1.6 99.2 0.19 0 94.6 0.3 1.5 99.5 0.44 0.5 92.8 0.55 3.0 94.4 1.4 0 96.3 97.7 2.7 1.4 5%SaC1 7 cisplatin Rem.

X TCAP Z Aquated sp.

ph 0.9xaCl Z cisplatin Rem. 94.5 95.5 96.5 90.7 93.6 89.9 91.5 91.5 90.3 93.3 88.3 89.5 89.9 Z TC-- 0 0 0.46 0.1 0.19 0.67 0.48 0.86 2.6 1.1 0.1 0.1 0.57 1.2 Aquated sp. 6.4 3.3 4.0 4.7 9.1 3.0 5.6 6.1 3.8 7.9 4.4 8.1 5.1 5%NaC1 cisplatin Rem. 100.8 100.1 100.9 97.2 100.3 94.7 97.2 95.8 96.7 100.5 99.8 94.0 96.7 TCAP 0 0 0.39 0.58 0.29 0.58 0.48 2.1 4.8 7.0 0.15 0.39 1.1 2.8 7 Aquated sp. 0 1.0 0 1.8 3.2 0.6 4.1 2.8 2.0 2.0 0.7 0.6 2.9 3.3 8 ~L 0 0 S o o o o S0 0 co o o o 0 o o o o o 000 0 0 It is evident from the data in Table I that solutions containing 5% sodium chloride contain significantly less of aquated species than solutions containing 0.9% sodium chloride at the same pH. Although 5% sodium chloride solutions show slightly elevated levels of trichloroamminoplatinum (TCAP), this is considered to be an acceptable compromise because TCAP is known to be far less acutely toxic than cisplatin or the aquated species. It is also evident from Table I that with 5% sodium chloride, the amount of intact cisplatin at pH 6.5 is comparable to that at pH 2.5 and pH 4.2 throughout the duration of the experiment. This is in sharp contrast to the 0.9% sodium chloride solution in which cisplatin is extensively degraded at pH 6.5 compared to pH 2.5 and 4.2. Thus, the ready-to-use cisplatin solutions of the present invention show similar stability profile to known ready-to-use solutions but without the disadvantage of high solution acidity.

The cisplatin solutions as described above may be lyophilized. The lyophilized product comprises for each part of cisplatini 25 to 100 parts of sodium chloride. A pharmaceutically acceptable filler, for example, mannitol may be optionally included in about 10 to 150 parts relative to cisplatin. The amount of sodium chloride should be sufficient to generate a solution having sodium chloride concentration of at least 45 mg/ml upon reconstitution with water. For example, a vial of the lyophilized dosage form may contain from 5 to 10 mg of cisplatin, 225 to 500 mg of sodium chloride and 50 to 500 mg of mannitol. The pH of the solution for lyophilization may be adjusted to a pH range of about 2 3 using hydrochloric acid; however, pH adjustment is not necessary. For clinical usage, the lyophilized cisplatin is first reconstituted with a conventional 9 L I I I parenteral diluent such as Water for Injection, U.S.P. to yield a solution containing 1 mg/ml of cisplatin.

The following is a typical procedure for preparing lyophilized cisplatin of the present invention.

1. In highly subdued indirect light for all the following and at 20 25 0 C, place approximately 900 ml of Water for Injection, U.S.P. in a suitable calibrated container.

2. Add, with rapid stirring, 50.0 g of sodium chloride and 10.0 g of mannitol. Stir until the ingredients are dissolved.

3. Sprinkle in 1.0 g of cisplatin over a 5 minute interval. Stir until the cisplatin is dissolved. Stir an additional 10 minutes.

4. Stop stirring and bring the volume to 1 liter with Water for Injection, U.S.P.

Stir vigorously for an additional 0.5 hour.

Using aseptic procedures: 6. Pass the solution under nitrogen pressure through a 0.2 micron pore size membrane filter and collect the filtrate.

7. Fill 10 ml of the solution into 20 ml amber flint glass vials.

8. Lyophilize at CoF for 72 hours and then at 80°F for 48 hours.

9. Insert 20 mm Daikyo stoppers and seal with aluminum closures.

10 According to the above procedure, each vial contains mg of cisplatin, 500 mg of sodium chloride, and 100 mg of mannitol.

The solid state stability of lyophilized cisplatin and the stability of reconstituted solutions were evaluated using four formulations A, B, C, and D, having the following compositions and characteristics: Formulation A B C D Cisplatin (mg/vial) 5 5 5 NaCI (mg/vial) 250 250 45 o 'o Mannitol (mg/vial) 50 50 50 HC1 1) pH (reconst. to -1 mg/ml)6.45 3.38 6.05 3.35 O o Cisplatin potency o o assayed directly 5.000 4.925 4.920 5.140 assayed with added 5.030 4.870 5.040 5.205 C1( 2 change 3 +0.6 -1.1 +2.4 +1.3 o 0 o 0 pH of pre-lyophilized solution was adjusted to o 0 using 1N HC1; pH not adjusted (pH 4.7-5.0).

0 (2) assayed following a two-fold dilution with pH 2.5 (HC1) ooo o 10% NaCl diluent.

general indicator of amount of aquated platinum species present.

11 1 Table II. Stability of lyophilized cisplatin solid of original cisplatin remaining Formulation 45 0 C 56 0

C

2 wk 99.8(0)2) 102.7(0) 97.3 (.69) 3 97.8 (.57) 3 4 wk 100.5(0) 98.7(.4) 97.4 3 98.0 (.58J3) 2 wk 99.1(0) 99.6(0) 97.8 97.0 (.77) 3 4 wk 100.0(0) 98.1(.3) 96.6 (.79)3) 97.4 (.86) 3 o 0 0 o 0 Reconstituted with Water for Injection, U.S.P. at the Time of assay.

2) S% TCAP shown in parenthesis.

3) SOriginal cisplatin potency is that determined with a two-fold dilution with pH 2.5 (HC1), 10% NaC1 diluent.

Table III. Stability of cisplatin reconstituted to 1 mq/ml and diluted with parenteral vehicles (24 0

C)

cisplatin remaining Diluted 10-fold Diluted Formulation with 5% Dextrose with 0.9% NaC1 4 hr 24 hr 4 hr 24 hr A 94.5 94.8 95.3 94.3 B 95.6 92.9 96.9 95.5 C 83.7 79.6 94.7 93.1 D 82.7 79.6 98.5 95.0 0 o 0 0p 00 s0 Table II shows that the examples of the present invention (formulations A and B) are more stable than the prior art systems (C and D) at extreme temperatures. Such compositions would be useful in tropical countries or other climates where storage of the product at 20 25 0 C cannot be 12- -4 vt? assured. The generally lower potencies of formulations C and D are due in part to the formation of aquated species as discussed previously.

The data in Table III indicate that the use of 5% NaCl in cisplatin lyophile allows dilution of the reconstituted solution into diverse diluents, including chloride-absent vehicles such as 5% dextrose. The percent cisplatin remaining at 4 and 24 hours show that dilution of reconstituted lyophile containing 0.9% NaC1 (Formulation C and D) in 5% dextrose would be unacceptable due to loss in potency and the formation of very large amounts of toxic aquated species. As also shown in Table III, a dilution of the reconstituted lyophile containing 5% NaC1 using normal saline NaC1) has equal potency to that of similarly diluted reconstituted lyophile containing 0.9% NaC1. This is due to a similar chloride concentration of about 1% NaCl in the final solutions.

It is noteworthy that all cisplatin reference standard solutions used for stability work were prepared freshly as 1 mg/ml cisplatin in 5% NaC1 0.05 N HC1 solutions.

This assures minimal formation of "aquated Pt species" in the standard. Cisplatin solutions prepared in water or normal saline would be lower in cisplatin potency due to rapid equilibration with "aquated-Pt-species", thus, assays using these standards may produce artificially high cisplatin potency.

It is to be understood that the scope of the invention is not limited by the compositions and parameters specifically exemplified to illustrate the invention, but is defined by the following claims.

13

I.

Claims

1. A stable aqueous solution of cisplatin in a sealed container suitable for parenteral administration comprising for each milliliter of solution up to 1.0 milligram of cisplatin and a pharmaceutically acceptable source of chloride ion in an amount equivalent to that produced by about 20 to 100 milligrams of sodium chloride, said solution having a pH of from about 5.0 to about

2. A solution of Claim 1 wherein said chloride source is sodium chloride.

3. A solution of Claim 1 wherein the pH of said solution is from about 5.6 to about o

4. A solution of Claim 1 wherein the pH of said solution is from about 6.0 to about A solution of Claim 1 wherein for each milliliter of solutions the amount of chloride ion is equivalent to that o produced by 40 to 60 milligrams of sodium chloride.

6. A solution of Claim 2 containing for each milliliter of solution about 40 to 60 milligrams of sodium chloride, said solution having a pH of from about 5.6 to about

7. A solution of Claim 6 wherein the pH of said solution is from about 6.0 to about

8. A solution of Claim 2 containing for each milliliter of solution about 0.2 to 1.0 milligram of cisplatin and about to 55 milligrams of sodium chloride, said solution having a pH of from about 5.6 to about 14 K 51 Li L i

9. A solution of Claim 8 wherein the pH of said solution is from about 6.0 to about A solution of Claim 8 containing for each milliliter of solution about 0.5 to 1.0 milligram of cisplatin and about milligrams of sodium chloride, said solution having a pH of from about 6.0 to about

11. A solution of Claim 10 wherein the pH of said solution is about

12. A pharmaceutical dosage form of cisplatin for o reconstitution with parenteral diluent which comprises for o 0 each part of cisplatin about 25 to 100 parts of sodium chloride, said dosage form being substantially free of lower o 0alkanol.

13. A dosage form of Claim 12 which further comprises about to 150 parts of a pharmaceutically acceptable filler.

14. A dosage form of Claim 13 wherein said filler is mannitol. C 0 A stable aqueous solution substantially as oo hereinbefore described with reference to any one of the Examples. I DATED: 13 November, 1989 PHILLIPS ORMONDE FITZPATRICK Attorneys for: BRISTOL-MYERS COMPANY 15